Cosmo Pharmaceuticals N.V.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cosmo Pharmaceuticals N.V. generated cash of $33,623,000, which is more than the previous year. Cash used in financing activities reached the amount of -$211,266,000 last year. Net change in cash is therefore -$135,550,000.
Cash Flow
| 2014 | 66.44M | -11.52M | -67.11M |
|---|---|---|---|
| 2015 | -39.22M | 78.93M | -2.57M |
| 2016 | 26.41M | 40.22M | -22.58M |
| 2017 | -10.00M | -22.30M | 72.67M |
| 2018 | -10.16M | -71.78M | 144.39M |
| 2019 | -18.84M | -48.68M | -34.46M |
| 2020 | 12.98M | 75.44M | -11.88M |
| 2021 | 12.61M | 24.85M | -27.24M |
| 2022 | 33.22M | 1.68M | -46.13M |
| 2023 | 33.62M | 42.30M | -211.26M |
0RGI.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 185.82M | 198.56M | 185.93M | 110.38M | 210.68M | 144.94M | 117.64M | 71.27M | 34.13M | 46.33M |
Operating activities | ||||||||||
Net income | 1.53M | 24.47M | 24.00M | -6.93M | -21.30M | -17.45M | -32.43M | 27.49M | 254.29M | 108.85M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 14.26M | 13.85M | 7.36M | 6.03M | 10K | 4.48M | 3.54M | 3.04M | 8.48M | 8.76M |
Stock-based compensation expense | 3.82M | 2.07M | 1.45M | 8.99M | 10.08M | 0 | 9.44M | 6.47M | 5.65M | 4.36M |
| Deferred income tax benefit | 3.82M | 2.07M | 1.45M | 8.99M | 10.08M | 0 | 9.44M | 6.47M | 5.65M | 4.36M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 5.19M | -14.16M | 3.29M | -7.91M | -3.71M | 0 | 1.77M | 0 | -13.52M | 0 |
Inventories | -2.7M | 1.62M | -6.07M | 436K | -2.20M | -696K | -937K | -57K | 1.07M | -467K |
Accounts payable | 0 | 14.16M | -3.29M | 7.91M | 3.71M | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 33.62M | 33.22M | 12.61M | 12.98M | -18.84M | -10.16M | -10.00M | 26.41M | -39.22M | 66.44M |
Investing activities | ||||||||||
Purchases Of Investments | -60.95M | -54.04M | -1.00M | -20.01M | -89.83M | -176.02M | -68.35M | -12.32M | -134.63M | -132.17M |
Investments In Property Plant And Equipment | -3.34M | -7.31M | -8.50M | -8.08M | -17.31M | -9.67M | -22.03M | -18.42M | -2.53M | -2.51M |
Acquisitions Net | 0 | 0 | 23.33M | -4.12M | 15.06M | -79K | -9.74M | -16.59M | 111.47M | -310K |
Cash generated by investing activities | 42.30M | 1.68M | 24.85M | 75.44M | -48.68M | -71.78M | -22.30M | 40.22M | 78.93M | -11.52M |
Financing activities | ||||||||||
Common Stock Issued | 687K | 270K | 761K | 5.25M | 0 | 0 | 96.25M | 0 | 255K | 0 |
Payments for dividends | -16.89M | -15.60M | 0 | 0 | 0 | 0 | -22.55M | -19.74M | 0 | -14.25M |
Repurchases of common stock | -12.47M | -24.74M | -19.74M | -10.97M | -25.33M | -18.35M | 0 | 0 | 0 | -52.12M |
Repayments of term debt | -176.02M | -916K | -2.62M | -1.78M | -1.75M | -665K | -854K | -2.97M | -2.82M | -2.00M |
Cash used in financing activities | -211.26M | -46.13M | -27.24M | -11.88M | -34.46M | 144.39M | 72.67M | -22.58M | -2.57M | -67.11M |
Net Change In Cash | -135.55M | -12.73M | 12.62M | 75.55M | -100.30M | 65.74M | 27.29M | 46.37M | 37.13M | -12.2M |
Cash at end of period | 50.27M | 185.82M | 198.56M | 185.93M | 110.38M | 210.68M | 144.94M | 117.64M | 71.27M | 34.13M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |